Biomea Fusion completes Phase II trial enrollment
Biomea Fusion completed enrollment for the Phase II icovamenib T2D study and dosed the first patient in a new combination trial, projecting cash runway into Q2 2027.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed